Literature DB >> 10813099

Inhibition of gonadotropin surge by a brief mid-cycle regimen of ethinyl estradiol and norethindrone: possible role in in vitro fertilization.

G S Letterie1.   

Abstract

Various methods to prevent premature luteinizing hormone (LH) surge and improve cycle control during hyperstimulation for in vitro fertilization (IVF) are standard of care. The purpose of the present study was to determine the influence of a 5-day regimen of ethinyl estradiol (EE) and norethindrone (NET) on folliculogenesis, gonadotropin surge, and ovulation. In a prospective randomized and comparative study, ten patients were assigned to two groups. A combination of 50 micrograms of EE and 1 mg of NET was used in groups I and II from days 6 through 10, and days 8 through 12, respectively. Blood samples and transvaginal ultrasound imaging were carried out throughout a 28-day cycle. Follicular diameter, plasma levels of LH, follicle-stimulating hormone (FSH), estradiol and progesterone, and endometrial thickness were determined. No LH surge or ovulation was detected in any patient studied. Peak estradiol concentrations were not significantly different between the groups (152.04 +/- 107.1 pg/ml vs 162.1 +/- 56.1 pg/ml [mean +/- SD] for groups I and II, respectively). No differences were noted between the groups for serum concentrations of FSH (range: 2-9 mIU/ml) or LH (range: 2-10 mIU/ml) for any given cycle day. Mean follicular diameters were not different between groups I and II (20.5 +/- 8.1 mm2 vs 20.6 +/- 14.2 mm2). Ultrasound assessment of mid-cycle follicular growth revealed diameters ranging from 18.5 mm2 to 34.0 mm2. Endometrial thickness ranged from 8 to 10 mm. There was no evidence of ovulation on ultrasound examination and either persistence or gradual resolution of follicles through the luteal phase. Peak serum concentrations at mid-luteal phase were < or = 2 ng/ml. In this pilot study, the combination of EE and NET restricted to a 5-day course beginning on day 6 or 8 permitted folliculogenesis but effectively inhibited midcycle LH surge and ovulation. Such regimens may have a role in IVF cycles for prevention of premature LH surges, especially as stimulation regimens evolve toward decreased gonadotropin use for stimulation and strict FSH preparations with the potential need for less complete pituitary suppression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10813099     DOI: 10.3109/09513590009167652

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  5 in total

1.  Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.

Authors:  Xiuxian Zhu; Xiaole Zhang; Yonglun Fu
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

2.  Comparison of neonatal outcomes following progesterone use during ovarian stimulation with frozen-thawed embryo transfer.

Authors:  Xiuxian Zhu; Hongjuan Ye; Yonglun Fu
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

3.  Lipidomic Components Alterations of Human Follicular Fluid Reveal the Relevance of Improving Clinical Outcomes in Women Using Progestin-Primed Ovarian Stimulation Compared to Short-Term Protocol.

Authors:  Xiaowei Wen; Yanping Kuang; Lixia Zhou; Baofeng Yu; Qiuju Chen; Yonglun Fu; Zheng Yan; Haiyan Guo; Qifeng Lyu; Jun Xie; Weiran Chai
Journal:  Med Sci Monit       Date:  2018-05-21

4.  Nimodipine, a calcium channel blocker, delays the spontaneous LH surge in women with regular menstrual cycles: a prospective pilot study.

Authors:  Dan Nayot; Shany Klachook; Robert F Casper
Journal:  Reprod Biol Endocrinol       Date:  2013-02-07       Impact factor: 5.211

5.  Effects of clomiphene citrate for prevention of premature luteinizing hormone surge in those undergoing intrauterine insemination outcome: A randomized, double-blind, placebo-controlled trial.

Authors:  Afsoon Zarei; Saeed Alborzi; Elham Askary; Mahshid Alborzi; Fatemeh Shahbazi
Journal:  J Adv Pharm Technol Res       Date:  2018 Jul-Sep
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.